Coming soon: New user interface

Dear CORE Diabetes Model User,

We are pleased to announce the IQVIA CORE Diabetes Model is being integrated into the IQVIA E360 platform. E360 is IQVIA’s browser-accessible online platform that facilitates real-time analytics with large datasets. The integration of the CORE Diabetes Model with the E360 platform will offer enhancements to the user experience, as well as greater levels of model stability. The new user interface is designed to be inherently intuitive, nevertheless training will be available on demand from September 2018 onwards.

During the upgrade over the next four weeks please be aware that there will be a 24-hour period in which the CORE Diabetes Model will be unavailable. The precise timeframe and dates for this process will be detailed in a later communication. We apologise for any inconvenience incurred by this. Please note that versions 8.5 (32 and 64 bit) and 9.0 32 bit will no longer be available once the integration with the E360 platform has been completed.

A new process for account and workspace administration will be introduced in order to maximise data security and comply will all new European data regulations. All procedures will be in line with the GDPR privacy guidelines. Users will have the ability to conveniently manage their own passwords and workspace assignments (groups/folders) through the E360 platform without needing support from IQVIA.

Once the CORE Diabetes Model has been launched on the E360 platform, a link will appear on the CDM website with instructions detailing the process users should follow in order to register their account with E360. Once registered, you will have access to all your existing groups, settings and simulations from version 9.0 (64 bit).

CORE Diabetes Model user-experience development will also be enhanced going forward; monthly updates will now provide new features and improvements on an ongoing basis. Scientific updates will continue to be released periodically as before. Release of the next scientific update of the model is foreseen at a later date in 2018.

The upgrades will result in a minor change to the random number generation during simulation, as a result existing simulation outcomes will change slightly. All changes will only be as a result of random variability and total outcomes are not expected to change by more than 2-3%. Apart from random variability, the computations run on the new system will be entirely equivalent to the versions run on the current system.

If you have any questions or concerns about this, please feel free to contact the team at CDMTeam@imshealth.com.

Kind Regards,

The CORE Diabetes Model Team

IQVIA CORE Diabetes Model update

Dear IQVIA CORE Diabetes model users,

IQVIA are pleased to inform all users that we will release the updated 64bit version of IQVIA CORE Diabetes Model (CDM) version 9.0 and version 8.5 by March 17 2017.

The transition to the updated 64 bit CDM infrastructure is part of a continued development programme to ensure that the CDM is hosted and processed on current state-of-the-art technology and software. This upgrade is associated with a number of benefits which are outlined below.

Simulation time – The number of simultaneous simulations that can be processed on the simulation severer system has been increased more than threefold which will considerably reduce the overall waiting time until simulation results can be accessed.

Stability – Recently an increasing number of simulation crashes have been observed (simulations being interrupted during execution and requiring restart) which contributed to the elongation of waiting time until outcomes can be accessed. With the upgrade to the new system it is expected that the stability of simulation processes will be substantially improved.

Security – The technologies used by 64bit CDM allow improvement to the security of the environment on which new CDM system is built. It will allow the development and deployment of resolutions to newly discovered threats as well as ensuring improved safety and integrity of data. SSL encryption of all communication between the user and web interface mean that all sensitive settings and simulation data will remain protected from outside interference and theft.

With this background information we kindly advise all CDM users to start using the new 64bit CDM versions as soon as possible.

The following URL link to the new 64bit CDM version can be used:

64bit CDM
CDM v9.0 and CDM v8.5: https://www.core-diabetes.com

The new versions will be fully equivalent to the current (32 bit) versions with the below exceptions:

• Due to the change to the 64bit infrastructure, the randomness of simulations has changed which means that simulations that are executed on the new system will present slight (random) deviations towards outcomes generated on the current versions. The magnitude of random variability is dependent on the simulation size (i.e. declines with increasing number of patients and/or bootstrap iterations included).
• The web interface appearance has changed slightly. Since the upgrade to 64 bit required a reimplementation of the web code, we took advantage of this update to change particular features which are explained in the attached update guide.

To access the 32bit versions, please use the following URL links:
32bit CDM
CDM v9.0: http://www.core-diabetes.com:8080/login.asp
CDM v8.5: http://www.core-diabetes.com:8080/CDM2012/login.asp

IQVIA CORE Diabetes Model User Group Forum

Dear CDM user,

The IQVIA Core Diabetes Model team will be at ISPOR in Milan in November, if you would like to attend a workshop on Sunday 8th November to find out more about the model please contact Mike Gains

Meeting Agenda

• Introduction to version 9.0 of the model
• Hypoglycaemic event module
• New type 2 risk equations
• Completely new Type 1 inputs based on new equations
• NICE comments on version 8.5 and how they are addressed in version 9
• Assessing the impact of BMI on cost-effectiveness
• FAQ’s on the CDM

If you already use the model and have any questions regarding the analyses you are running please send all your questions and remarks to mlamotte@be.imshealth.com

Mark Lamotte
Senior Principal - Cardiologist
Real-World Evidence Solutions & HEOR
IQVIA

CDM USER FORUM - ISPOR Milan 2015

IQVIA CORE Diabetes Model Version 9.0

Dear user,

On July 13 2015 we launched version 9.0 of the CDM.
This updated version includes additional risk equation, a new module on hypoglycaemia, a complete rework of type 1 diabetes including the most recent available information, as well as a revised user interface.

If you want to use version 9.0 please click here www.core-diabetes.com

If you want to continue using version 8.5 please click here www.core-diabetes.com/cdm2012

Version 9.0 has been thoroughly tested however this does not exclude that there are still errors. Please e-mails us at info_CDM@imshealth.com if you face any issue.

Looking forward to hear from you,

Mark Lamotte, MD

Scientific Leader CDM

A tool for policy analysis and reimbursement strategy in diabetes

The IQVIA CORE Diabetes Model (IQVIA CDM) simulates disease progression in both type 1 and type 2 diabetes. The model is a tool that can be used to explore economic value over the course of a product’s lifecycle. Potential applications include identification of clinical development priorities, pricing evaluation, health technology assessment and post-launch market access support. The IQVIA CDM is a computer simulation model designed to take surrogate endpoints and translate them in to long term health economic outcomes:

The IQVIA CDM is the most widely adopted economic model in diabetes available to users from academia, and health care industries, as well as health care payers and decision makers.

• The model has undergone an extensive validation process.
• It is continually updated to include the latest clinical and epidemiological data as well as to implement functional improvements.
• Results from the model have been widely published, with over 80 peer-reviewed publications.
• 7 of the 10 largest diabetes drug and device manufacturers are using the CDM.